Skip to main content
HUMHumana Inc.Sell5.1·$389.32-1.31%
SellModerate Confidence
Investment thesis

Humana carries four consecutive earnings beats and 24% revenue growth, but severe operating margin deterioration has triggered value-trap flags, the stock trades above its near-term resistance level with an unfavorable risk/reward, and an unresolved legal disclosure adds a layer of uncertainty—leaving the setup unattractive for new exposure until the fundamental picture clarifies.

Thesis pillars

  • Severe Margin Deterioration Value TrapDeteriorating
  • Consistent Earnings Beat StreakStable
  • Above Resistance Unfavorable Risk RewardStable
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Humana Inc. (HUM) Stock Analysis

SellGrowthShortModerate Confidence

Healthcare · Healthcare Plans

Earnings in 4 days (2026-07-29). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $389.32: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: Below-average business quality; Negative price momentum.

Humana provides Medicare Advantage health plans, Medicaid managed care, and CenterWell primary care and pharmacy services, with Medicare representing 82.6% of Insurance segment premiums. In 2025, the company served approximately 15 million medical plan members; 83% of total... Read more

$389.32-19.6% A.UpsideScore 5.1/10#10 of 11 Healthcare Plans
QualityF-score7 / 9FCF yield3.06%
IncomeYield0.90%(5y avg 0.97%)Payout37.78%sustainable
Stop $362.07Target $420.30(resistance)A.R:R -2.7:1
Analyst target$347.96-10.6%24 analysts
$420.30our TP
$389.32price
$347.96mean
$195
$502

Sell if holding. Engine safety override at $389.32: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.1/10, moderate confidence.

Passes 5/8 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 4d<=7d. Suitability: moderate.

10-K grounded · weekly refresh

About Humana Inc.

About Humana Inc.

Humana served approximately 15 million medical plan members at December 31, 2025, generating $123.8 billion in Insurance segment premiums and services revenue. Individual Medicare Advantage contributed $90.4 billion, or 70.3% of consolidated premiums and services revenue, while Total Medicare reached 82.6%. The company's CenterWell segment operated 350 primary care clinics and CenterWell Home Health across 37 states.

Humana earns revenue almost entirely from per-member-per-month payments from CMS for Medicare Advantage and Part D plans, supplemented by state Medicaid managed care contracts in Florida, Kentucky, Illinois, Indiana, Louisiana, Ohio, Oklahoma, South Carolina, Virginia, and Wisconsin. The 10-K discloses that approximately 93% of total premiums and services revenue came from federal and state government health care programs in 2025. Premium rates are set annually through CMS bid submissions and adjusted via a risk-adjustment model that pays more where member health status indicates higher expected costs — the company flags that inaccuracies in provider coding submitted to CMS expose it to Risk-Adjustment Data Validation audits. CenterWell's 350 primary care clinics and CenterWell Home Health generate additional revenue from external third-party payer and Medicare Advantage relationships. The company competes for Medicare enrollment during the annual October 15–December 7 enrollment window against large national insurers.

Show full overview

Florida concentrates 14% of consolidated premiums and services revenue in a single CMS contract cluster covering approximately 1.0 million individual Medicare Advantage members, a loss of which the 10-K characterizes as potentially material to results. Separately, Humana's Medicare Advantage plans experienced a significant decline in 4-star or higher Star Ratings for 2025, which the company has challenged through litigation. If that lawsuit fails, reduced quality bonus payments from CMS could weigh on 2026 revenues and trigger further membership attrition at the next annual enrollment period.

See also: Healthcare · Healthcare Plans

From Humana Inc.'s most recent 10-K filing, extracted June 10, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-07-25
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Wed, Jul 29, 20264d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Target reached (-19.6% upside)
Quality below floor (4.0 < 4.0)

Key Metrics

P/E (TTM)41.5
P/E (Fwd)24.3
Mkt Cap$46.7B
EV/EBITDA11.7
Profit Mgn0.8%
ROE6.3%
Rev Growth23.5%
Beta0.72
Dividend0.90%
Rating analysts33

Quality Signals

Piotroski F7/9MoatNarrow

Options Flow

P/C0.54bullish
IV77%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Volume
0.4
Obv
1.0
Rsi
5.5
Ma Position
6.0
Volume distribution (falling OBV)Above 200-day MA
GatesMomentum 2.6<4.5A.R:R -2.7=NEGATIVEEARNINGS PROXIMITY 4d<=7dInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Moderate
RSI
48 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $372.61Resistance $428.88

Price Targets

$362
$420
A.Upside-19.6%
A.R:R-2.7:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (-19.6% upside)
! Quality below floor (4.0 < 4.0)
! momentum at 2.6 (below the engine's 4.5 threshold)

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-07-29 (4d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is HUM stock a buy right now?

Sell if holding. Engine safety override at $389.32: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $362.07. Score 5.1/10, moderate confidence.

What is the HUM stock price target?

Take-profit target: $420.30 (-19.6% upside). Prior stop was $362.07. Stop-loss: $362.07.

What are the risks of investing in HUM?

Target reached (-19.6% upside); Quality below floor (4.0 < 4.0).

Is HUM overvalued or undervalued?

Humana Inc. trades at a P/E of 41.5 (forward 24.3). TrendMatrix value score: 4.9/10. Verdict: Sell.

What do analysts say about HUM?

33 analysts cover HUM with a consensus score of 3.5/5. Average price target: $348.

What does Humana Inc. do?Humana provides Medicare Advantage health plans, Medicaid managed care, and CenterWell primary care and pharmacy...

Humana provides Medicare Advantage health plans, Medicaid managed care, and CenterWell primary care and pharmacy services, with Medicare representing 82.6% of Insurance segment premiums. In 2025, the company served approximately 15 million medical plan members; 83% of total premiums and services revenue came from federal government contracts. Florida alone accounts for 14% of consolidated premiums via individual Medicare Advantage.

Related stocks: CI (The Cigna Group) · OSCR (Oscar Health, Inc.) · UNH (UnitedHealth Group Incorporated) · CVS (CVS Health Corporation) · CNC (Centene Corporation)
Home Stocks HUM

Latest news

Latest News

Benzinga4d ago
Benzinga5d ago
Benzinga8d ago
Benzinga9d ago
Benzinga9d ago
Benzinga11d agoAnalyst
Benzinga11d agoAnalyst
Benzinga12d agoAnalyst
Benzinga16d agoAnalyst
Benzinga18d agoAnalyst
Benzinga21d ago
Benzinga25d agoProduct
Benzinga31d agoAnalyst
Benzinga44d agoAnalyst
Benzinga44d agoLegal
Benzinga45d ago
Benzinga47d ago
Benzinga47d agoAnalyst
Benzinga51d ago
Benzinga51d agoAnalyst
Loading more...